| Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review RM Stoekenbroek, TB Santema, DA Legemate, DT Ubbink, ... European journal of vascular and endovascular surgery 47 (6), 647-655, 2014 | 224 | 2014 |
| Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower- Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized … KTB Santema, RM Stoekenbroek, MJW Koelemay, JA Reekers, ... Diabetes care 41 (1), 112-119, 2018 | 171 | 2018 |
| Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1 KK Ray, RM Stoekenbroek, D Kallend, LA Leiter, U Landmesser, ... Circulation 138 (13), 1304-1316, 2018 | 164 | 2018 |
| Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial KK Ray, RM Stoekenbroek, D Kallend, T Nishikido, LA Leiter, ... JAMA cardiology 4 (11), 1067-1075, 2019 | 136 | 2019 |
| Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies RS Wright, MG Collins, RM Stoekenbroek, R Robson, PLJ Wijngaard, ... Mayo Clinic Proceedings 95 (1), 77-89, 2020 | 128 | 2020 |
| Inhibiting PCSK9—biology beyond LDL control RM Stoekenbroek, G Lambert, B Cariou, GK Hovingh Nature Reviews Endocrinology 15 (1), 52-62, 2019 | 119 | 2019 |
| Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program RM Stoekenbroek, D Kallend, PLJ Wijngaard, JJP Kastelein Future cardiology 14 (6), 433-442, 2018 | 95 | 2018 |
| Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the … GK Hovingh, NE Lepor, D Kallend, RM Stoekenbroek, PLJ Wijngaard, ... Circulation 141 (22), 1829-1831, 2020 | 85 | 2020 |
| PCSK9 inhibitors in clinical practice: delivering on the promise? RM Stoekenbroek, ML Hartgers, R Rutte, DD de Wijer, ESG Stroes, ... Atherosclerosis 270, 205-210, 2018 | 70 | 2018 |
| Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified … U Landmesser, A Haghikia, LA Leiter, RS Wright, D Kallend, P Wijngaard, ... Cardiovascular research 117 (1), 284-291, 2021 | 55 | 2021 |
| PCSK9 inhibition: the way forward in the treatment of dyslipidemia RM Stoekenbroek, JJP Kastelein, R Huijgen BMC medicine 13, 1-6, 2015 | 54 | 2015 |
| Systemic wound care: a meta-review of cochrane systematic reviews. DT Ubbink, TB Santema, RM Stoekenbroek Surgical technology international 24, 99-111, 2014 | 54 | 2014 |
| PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia R Verbeek, RM Stoekenbroek, GK Hovingh European journal of pharmacology 763, 38-47, 2015 | 52 | 2015 |
| Hide and seek: does the toe-brachial index allow for earlier recognition of peripheral arterial disease in diabetic patients? RM Stoekenbroek, DT Ubbink, JA Reekers, MJW Koelemay European Journal of Vascular and Endovascular Surgery 49 (2), 192-198, 2015 | 49 | 2015 |
| How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population RM Stoekenbroek, JLC Lokin, MM Nielen, ESG Stroes, MJW Koelemay Diabetologia 60, 1271-1275, 2017 | 47 | 2017 |
| Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study RM Stoekenbroek, SM Boekholdt, R Luben, GK Hovingh, AH Zwinderman, ... European heart journal 37 (11), 880-889, 2016 | 47 | 2016 |
| ApoA-I mimetics RM Stoekenbroek, ES Stroes, GK Hovingh High Density Lipoproteins: From Biological Understanding to Clinical …, 2015 | 47 | 2015 |
| Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment D Kallend, R Stoekenbroek, YL He, PF Smith, P Wijngaard Journal of Clinical Lipidology 16 (2), 208-219, 2022 | 45 | 2022 |
| High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease RM Stoekenbroek, SM Boekholdt, R Fayyad, R Laskey, MJ Tikkanen, ... Heart 101 (5), 356-362, 2015 | 45 | 2015 |
| Is additional hyperbaric oxygen therapy cost‐effective for treating ischemic diabetic ulcers? Study protocol for the D utch DAMOCLES multicenter randomized clinical trial 对缺 … RM Stoekenbroek, TB Santema, MJW Koelemay, RA van Hulst, ... Journal of diabetes 7 (1), 125-132, 2015 | 42 | 2015 |
